Detection of the active components of calf thymus nuclear proteins (TNP), histones that are binding with high affinity to HIV-1 envelope proteins and CD4 molecules

Current HIV Research

Volumn 6, Issue 4, 2008, Pages 318-326

  Mamikonyan, Grigor ^a   Kiyatkin, Anatoly ^b   Movsesyan, Nina ^a,c   Mkrtichyan, Mikayel ^a   Ghochikyan, Anahit ^a   Petrushina, Irina ^c   Hwang, Jimmy ^d   Ichim, Thomas E ^a   Keledjian, Haig ^e   Agadjanyan, Michael G ^a,c  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Viral Genetics Inc   (United States)

Author keywords

Binding to gp41; CD4; gp120; Histones; Thymus nuclear proteins (TNP); VGV 1TM

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HISTONE; HISTONE H1; HISTONE H2A; HISTONE H2B; HISTONE H4; NUCLEAR PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VGV 1; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG FORMULATION; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOAFFINITY CHROMATOGRAPHY; MOLECULAR MECHANICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; PROTEIN DATABASE; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SURFACE PLASMON RESONANCE; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTIGENS, CD4; CARRIER PROTEINS; CATTLE; HISTONES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; NUCLEAR PROTEINS; PROTEIN BINDING; SURFACE PLASMON RESONANCE; THYMUS GLAND;

EID: 52449110328     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208785132545     Document Type: Review

References (34)

1. Bokazhanova A, Rutherford GW. The epidemiology of HIV and AIDS in the world. Coll Antropol 2006; 30(Suppl 2): 3-10.
2. Flexner C. HIV drug development: the next 25 years. Nat Rev Drug Discov 2007; 6(12):959-66.
3. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol 2003; 21:139-76.
4. Gieldanowski J, Kowalczyk-Bronisz SH. Investigations on immunological and pharmacological activities of thymus factor X/TFX. Arch Immunol Ther Exp (Warsz) 1978; 26(1-6): 483-5.
5. Skotnicki AB, Zatz M, Sztein MB, Goldstein AL, Schulof RS. Effect of thymic hormones on interleukin 2 synthesis by lymphocytes from HIV-positive pre-AIDS subjects. Immunol Invest 1988;17(2):159-64.
6. Ben-Efraim S, Keisari Y, Ophir R, Pecht M, Trainin N, Burstein Y. Immunopotentiating and immunotherapeutic effects of thymic hormones and factors with special emphasis on thymic Immoral factor THF-gamma2. Crit Rev Immunol 1999; 19(4): 261-84.
7. Calenda V, Silvy F, Chermann JC. Effects of thymus Immoral factor gamma-2 (THF gamma 2) on lymphohaematopoietic progenitor cells: an in vitro study. Res Immunol 1993;144(6-7):395-406.
8. Dardenne M, Bach JF, Safai B. Low serum thymic hormone levels in patients with acquired immunodeficiency syndrome. N Engl J Med 1983;309(1):48-9.
9. Zhabilov H, Keledjian H. Compositions and methods for detecting and treating acquired immunodeficiency syndrome United States Patent Application 20040018639 2004; January 29.
10. http://www.viralgenetics.com/VGEN_INV_FACTSHEET.pdf March, 2008.
11. Zhabilov H, Karavassileff., Todor Y. Compositions, processes for their preparation and method for treatment of neoplasms United States Patent 4,415,553. 1983 November 15.
12. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996; 68(5): 850-8.
13. Gatlin CL, Kleemann GR, Hays LG, Link AJ, Yates JR, 3rd. Protein identification at the low femtomole level from silver-stained gels using a new fritless electrospray interface for liquid chromatography-micro spray and nanospray mass spectrometry. Anal Biochem 1998; 263(1): 93-101.
14. Eng J, McCormack AL, Yates JR, III. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database J Am Soc Mass Spectrom 1994; 5(11): 976-89.
15. Tabb DL, McDonald WH, Yates JR, 3rd. DTASelect and Contrast: tools for assembling and comparing protein identifications from shotgun proteomics. J Proteome Res 2002; 1(1): 21-6.
16. Washburn MP, Wolters D, Yates JR, 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 200 1; 19(3): 242-7.
17. Johnston MI, Fauci AS. An HIV vaccine - evolving concepts. N Engl J Med 2007; 356(20): 2073-81.
18. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24: 739-69.
19. Chang DK, Cheng SF, Trivedi VD. Biophysical characterization of the structure of the amino-terminal region of gp4l of HIV-1. Implications on viral fusion mechanism. J Biol Chem 1999; 274(9): 5299-309.
20. Tamura M, Natori K, Kobayashi M, Miyamura T, Takeda N. Inhibition of attachment of virions of Norwalk virus to mammalian cells by soluble histone molecules. Arch Virol 2003; 148(9): 1659-70.
21. Lesner A, Kartvelishvili A, Lesniak J, et al. Monoubiquitinated histone H1B is required for antiviral protection in CD4(+)T cells resistant HIV-1. Biochemistry 2004; 43(51):16203-11.
22. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms ofaction. Oncogene 2007; 26(37):5541-52.
23. Kurien BT, Scofield RH. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand J Immunol 2006; 64(3): 227-35.
24. Furnrohr BG, Groer GJ, Sehnert B, Herrmann M, Voll RE. Interaction of histones with phospholipids - implications for the exposure of histones on apoptotic cells. Autoimmunity 2007; 40(4): 322-6.
25. Anders HJ. A Toll for lupus. Lupus 2005; 14(6): 417-22.
26. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54(6): 1906-16.
27. Cernescu CE. AIDS vaccines and adjuvant formulations. Int J Immunopharmacol 1994; 16(5-6): 369-79.
28. Fultz PN, Siegel RL, Brodie A, et al. Prolonged CD4+ lymphocytopenia and thrombocytopenia in a chimpanzee persistently infected with human immunodeficiency virus type 1. J Infect Dis 1991; 163(3): 441-7.
29. Fultz PN, Stricker RB, McClure HM, Anderson DC, Switzer WM, Horaist C. Humoral response to SIV/SMM infection in macaque and mangabey monkeys. J Acquir Immune Defic Syndr 1990; 3(4): 319-29.
30. Williams WM, Whalley AS, Comacchio RM, et al. Correlation between expression of antibodies to histone H2B and clinical activity in HIV-infected individuals. Clin Exp Immunol 1996; 104(1): 18-24.
31. Watson K, Edwards RJ, Shaunak S, et al. Extra-nuclear location of histones in activated human peripheral blood lymphocytes and cultured T-cells. Biochem Pharmacol 1995; 50(3): 299-309.
32. Bosque A, Pardo J, Martinez-Lorenzo MJ, et al. Down-regulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL, and c- FLIP, Bim, or Bcl-x isoform expression. J Leukoc Biol 2005; 77(4): 568-78.
33. Ott M, Emiliani S, Van Lint C, et al. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997; 275(5305): 1481-5.
34. Hsu LW, Goto S, Nakano T, et al. The effects of anti-histone H1 antibody on immune cells responsible for rejection reaction. Mol Immunol 2005; 42(10): 1155-64.